Human 3D Gastrointestinal Microtissue Barrier Function As a Predictor of Drug-Induced Diarrhea.
diarrhea
enteroid
gastrointestinal
intestine
microtissue
organoid
toxicity
Journal
Toxicological sciences : an official journal of the Society of Toxicology
ISSN: 1096-0929
Titre abrégé: Toxicol Sci
Pays: United States
ID NLM: 9805461
Informations de publication
Date de publication:
01 03 2019
01 03 2019
Historique:
pubmed:
27
10
2018
medline:
18
3
2020
entrez:
27
10
2018
Statut:
ppublish
Résumé
Drug-induced gastrointestinal toxicities (GITs) rank among the most common clinical side effects. Preclinical efforts to reduce incidence are limited by inadequate predictivity of in vitro assays. Recent breakthroughs in in vitro culture methods support intestinal stem cell maintenance and continual differentiation into the epithelial cell types resident in the intestine. These diverse cells self-assemble into microtissues with in vivo-like architecture. Here, we evaluate human GI microtissues grown in transwell plates that allow apical and/or basolateral drug treatment and 96-well throughput. Evaluation of assay utility focused on predictivity for diarrhea because this adverse effect correlates with intestinal barrier dysfunction which can be measured in GI microtissues using transepithelial electrical resistance (TEER). A validation set of widely prescribed drugs was assembled and tested for effects on TEER. When the resulting TEER inhibition potencies were adjusted for clinical exposure, a threshold was identified that distinguished drugs that induced clinical diarrhea from those that lack this liability. Microtissue TEER assay predictivity was further challenged with a smaller set of drugs whose clinical development was limited by diarrhea that was unexpected based on 1-month animal studies. Microtissue TEER accurately predicted diarrhea for each of these drugs. The label-free nature of TEER enabled repeated quantitation with sufficient precision to develop a mathematical model describing the temporal dynamics of barrier damage and recovery. This human 3D GI microtissue is the first in vitro assay with validated predictivity for diarrhea-inducing drugs. It should provide a platform for lead optimization and offers potential for dose schedule exploration.
Identifiants
pubmed: 30364994
pii: 5145097
doi: 10.1093/toxsci/kfy268
pmc: PMC6390652
doi:
Substances chimiques
Pharmaceutical Preparations
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3-17Subventions
Organisme : NIGMS NIH HHS
ID : R44 GM108164
Pays : United States
Informations de copyright
© The Author(s) 2018. Published by Oxford University Press on behalf of the Society of Toxicology.
Références
Eur J Pharm Biopharm. 2015 Sep;95(Pt A):77-87
pubmed: 25857839
Altern Lab Anim. 2002 Mar-Apr;30(2):151-76
pubmed: 11971753
Exp Biol Med (Maywood). 2017 Oct;242(16):1633-1642
pubmed: 28534432
CPT Pharmacometrics Syst Pharmacol. 2018 Jan;7(1):26-33
pubmed: 28941225
PLoS One. 2016 Apr 27;11(4):e0154351
pubmed: 27119373
Eur J Endocrinol. 2016 Apr;174(4):465-72
pubmed: 26764417
NPJ Breast Cancer. 2016 Mar 30;2:16006
pubmed: 28721374
Toxicol Appl Pharmacol. 2017 Nov 1;334:100-109
pubmed: 28893587
Drug Metab Pharmacokinet. 2011;26(1):3-14
pubmed: 20978361
Regul Toxicol Pharmacol. 2000 Aug;32(1):56-67
pubmed: 11029269
Arch Intern Med. 2006 Jan 23;166(2):155-60
pubmed: 16432082
Breast Cancer Res Treat. 2016 Nov;160(1):91-99
pubmed: 27654971
Nature. 2015 Jun 11;522(7555):173-8
pubmed: 26040716
Biomaterials. 2017 Jun;128:44-55
pubmed: 28288348
Toxicol Sci. 2012 Mar;126(1):275-84
pubmed: 22157355
Toxicol Sci. 2013 Dec;136(2):581-94
pubmed: 24052561
Cell Mol Gastroenterol Hepatol. 2018 Jan 17;5(3):440-453.e1
pubmed: 29675459
Nat Cell Biol. 2016 Mar;18(3):246-54
pubmed: 26911908
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Nature. 2009 May 14;459(7244):262-5
pubmed: 19329995
Drug Discov Today. 2010 Sep;15(17-18):704-16
pubmed: 20601093
Nat Med. 2009 Jun;15(6):701-6
pubmed: 19398967
Handb Exp Pharmacol. 2015;229:291-321
pubmed: 26091645
Methods Mol Biol. 2016;1422:33-40
pubmed: 27246020
Br J Cancer. 2008 Jun 17;98(12):1951-8
pubmed: 18506143
Histochem Cell Biol. 2011 Jul;136(1):103-15
pubmed: 21681518
Toxicol Sci. 2012 Mar;126(1):114-27
pubmed: 22166485
Nat Med. 2013 Jul;19(7):939-45
pubmed: 23727931
Cell Death Dis. 2014 May 15;5:e1228
pubmed: 24832600
J Cancer Res Clin Oncol. 2014 Feb;140(2):221-6
pubmed: 24292401
Toxicol Sci. 2018 Mar 1;162(1):200-211
pubmed: 29126144
Gut. 2018 Feb 21;:
pubmed: 29467166
Cardiovasc Res. 2003 Apr 1;58(1):32-45
pubmed: 12667944
Ther Adv Med Oncol. 2010 Jan;2(1):51-63
pubmed: 21789126
Cell Stem Cell. 2016 Jan 7;18(1):25-38
pubmed: 26748754
Neurogastroenterol Motil. 2014 Jul;26(7):980-9
pubmed: 24813024
Curr Gastroenterol Rep. 2007 Oct;9(5):365-72
pubmed: 17991336
J Pharmacol Toxicol Methods. 2007 Mar-Apr;55(2):176-83
pubmed: 16891127
Assay Drug Dev Technol. 2016 Dec;14(10):557-566
pubmed: 27631620
Pharm Res. 2018 Feb 23;35(4):72
pubmed: 29476278
Nat Med. 2014 Jul;20(7):769-77
pubmed: 24859528
Nat Rev Gastroenterol Hepatol. 2017 Jan;14(1):9-21
pubmed: 27848962
Drug Discov Today. 2009 Feb;14(3-4):162-7
pubmed: 19100337
Best Pract Res Clin Gastroenterol. 2012 Oct;26(5):633-48
pubmed: 23384808
Clin Pharmacol Ther. 2015 Jan;97(1):37-54
pubmed: 25670382
Gastroenterology. 2016 Feb 18;:
pubmed: 27144621
J Lab Autom. 2015 Apr;20(2):107-26
pubmed: 25586998
Nat Rev Drug Discov. 2014 Jun;13(6):419-31
pubmed: 24833294
Sci Rep. 2016 Nov 09;6:36795
pubmed: 27827428